Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.71 |
| ▸ | MAPT | P10636 | 8/20 | 0.71 |
| ▸ | RAB9A | P51151 | 8/20 | 0.71 |
| ▸ | NPC1 | O15118 | 7/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | STAT1 | P42224 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | GFER | P55789 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1747328 | 0.87 | RAB9A (0.81) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL3255454 | 0.86 | MAPT (0.71) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL918935 | 0.85 | RAB9A (0.74) | MEN1KMT2AMAPTRAB9ANPC1 | |
| Bromide SCHEMBL3252043 | 0.85 | MAPT (0.69) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL10475630 | 0.84 | MAPT (0.91) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL1745328 | 0.83 | MAPT (0.62) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL1724171 | 0.83 | MAPT (1.00) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL29470100 | 0.82 | RAB9A (0.61) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL21517172 | 0.82 | MAPT (0.61) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL29419343 | 0.82 | MAPT (0.69) | MEN1KMT2AMAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3800186-B1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LTD (GB) | 2024-10-02 | — | — | EP | disclosed |
| US-11319287-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | MISSION THERAPEUTICS LIMITED (GB) | 2022-05-03 | — | — | US | disclosed |
| US-11319287-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | MISSION THERAPEUTICS LIMITED (GB) | 2022-05-03 | — | — | US | disclosed |
| EP-3416960-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| EP-3416960-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| CN-108699035-B | Novel compounds | 特殊治疗有限公司 | 2021-10-15 | — | — | CN | disclosed |
| US-20200231542-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2020-07-23 | — | — | US | disclosed |
| US-10669234-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-02 | — | — | US | disclosed |
| US-10640498-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2020-05-05 | — | — | US | disclosed |
| US-10640498-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2020-05-05 | — | — | US | disclosed |
| WO-2017141036-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED (GB) | 2017-08-24 | — | — | WO | disclosed |
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| CN-101878211-A | Aminothiazole derivs | HOFFMANN LA ROCHE | 2010-11-03 | — | — | CN | disclosed |
| EP-2227468-A1 | AMINOTHIAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009068467-A1 | AMINOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | WO | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| CN-1735408-A | Receptor function controlling agent | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-15 | — | — | CN | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669234-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | USP30, USP39, UCHL1 | MEN1 3738/4885KMT2A 2211/4885MAPT 3325/4885 |
| US-10640498-B2 | Compounds | USP30, USP20, UBQLN1 | MEN1 3967/4885KMT2A 2948/4885MAPT 1970/4885 |
| US-20200231542-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | USP30, USP39, UCHL1 | MEN1 3738/4885KMT2A 2211/4885MAPT 3325/4885 |
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | MEN1 2579/4885KMT2A 4408/4885MAPT 4718/4885 |
| US-11319287-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | USP30, USP39, UCHL1 | MEN1 3738/4885KMT2A 2211/4885MAPT 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.